JAYESH & GOSAI, MD
LIONS MEDICAL CENTER
1895 Jefferson Road, Rices Landing, PA 15357 Phone 724-883-2223 or 883-3128
MAILING ADDRESS
P.O. Box 470, Jefferson, Pennsylvania 15344

May 5, 2005

37-30623-01
03035648

U.S. Nuclear Regulatory Commission
Nuclear Materials Safety Branch
Radioactive Material Licensing
Region I
King of Prussia, PA 19406

'05 MAY 10 P1:08
RECEIVED

RE: 37-30623-01

Please expedite this licensing request.

Dear License Reviewer:

Please amend the above referenced material license to reflect the following modification:

1. Amend to add Susan M. Geletka, M.D., as an authorized user. Dr. Geletka is currently listed as an authorized user on other radioactive material licenses and therefore satisfies the training and experience requirements. Please see the attached documentation of her licensure and certification.

All other items relating to our radioactive material license and established radiation safety program remain unchanged at this time.

Please contact me at 724.883.3000 regarding any questions and/or concerns, you may have. Thank you for your prompt assistance regarding this matter.

Sincerely,

Val Babu, MD
Radiation Safety Officer
Lions Medical Center

137057
NMSS/RGN1 MATERIALS-002

Geletka, Susan M.

DISPLAY THIS CERTIFICATE PROMINENTLY • NOTIFY AGENCY WITHIN 10 DAYS OF ANY CHANGE

Commonwealth of Pennsylvania
Department of State
Bureau of Professional and Occupational Affairs
PO Box 2649 Harrisburg PA 17105-2649

04-022846

License Type
Medical Physician and Surgeon

License Status
Active

Initial License Date
04/27/1984

SUSAN MARY GELETKA
9275 WEST CALLA ROAD
CANFIELD OH 44406-9459

License Number
MD031019E

Expiration Date
12/31/2006

Commissioner of Professional and Occupational Affairs

Signature

ALTERATION OF THIS DOCUMENT IS A CRIMINAL OFFENSE UNDER 18 PA.C.S.S. 4911

Geletka, Susan M.

C-46123

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine
Hereby certifies that

Susan Mary Geletka, M.D.

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology
On this seventh day of November, 1995
Thereby demonstrating to the satisfaction of the Board
that she is qualified to practice the specialty of

Diagnostic Radiology

THE AMERICAN BOARD OF RADIOLOGY
INCORPORATED IN THE DISTRICT OF COLUMBIA
1934

President — Secretary — Executive Director

Geletka, Susan M. G.76/123

The Youngstown Hospital Association

of

Youngstown, Ohio

Associated with the Northeastern Ohio Universities College of Medicine

This Certifies that

Susan M. Geletka, M.D.

has faithfully and satisfactorily served
a First Post Graduate Year in Diagnostic Radiology
July 1, 1980 through June 30, 1981

Richard J. Wigand
President

Franklin S. Bennett
Chairman, Board of Trustees

Robert A. Weitzel, M.D.
Vice President, Medical Affairs

Gerald Battles, M.D.
President, Clinical Staff

The Youngstown Hospital Association

of

Youngstown, Ohio

Associated with the Northeastern Ohio Universities College of Medicine

This Certifies that

Susan M. Geletka, M.D.

has faithfully and satisfactorily served
as Resident in Diagnostic Radiology
July 1, 1981 through June 30 1984

President

Chairman, Board of Trustees

Vice President, Medical Affairs

President, Clinical Staff

Geletka, Susan M. 6/26/23

9. Authorized Use:

   A. Any uptake, dilution, and excretion study permitted by 10 CFR 35.100.

   B. Any imaging and localization study permitted by 10 CFR 35.200.

   C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

   D. *In vitro* studies permitted by 10 CFR 31.11

   E. For use in human research to study the effect of visceral obesity on muscle FFA utilization.

   F. through M. Research and development as defined in 10 CFR 30.4, including animal studies, instrument calibration, student instruction, and *in vitro* studies.

   N. For instrument calibration using Tech Ops Model 773 or Nuclear Associates Model 64-764.

   O. For use in an ADAC Laboratories Model Vantage device for patient attenuation correction during SPECT imaging.

CONDITIONS

10. Permitted material may be used or stored at the permittee's facilities located at University Drive, Pittsburgh, Pennsylvania, and 7180 Highland Drive, Pittsburgh, Pennsylvania.

11. The Radiation Safety Officer for this permit is Yingchieh Hsu, Ph.D.

12. Permitted material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user and/or an authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.

    B. The following individuals are authorized users for the material and uses indicated:

Authorized Users	Material and Use
Herbert Klein, M.D., Ph.D.	35.100, 35.200, 35.300, *in vitro* studies, Gadolinium 153
Ajit Shah, M.D.	35.100, 35.200, 35.300, *in vitro* studies, Gadolinium 153
Andrew Scott La Pidus, M.D.	35.100, 35.200, 35.300, *in vitro* studies, Gadolinium 153
Frank A. Mino, M.D.	35.100, 35.200, 35.300, *in vitro* studies, Gadolinium 153
Janet A. Amico, M.D.	Phosphorus 32, Sulfur 35, Iodine 125
Patricia A. Craven, Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Sulfur 35, Chromium 51, Iodine 125
Timothy Carlos, M.D.	Hydrogen 3, Chromium 51
Jau-Shyong Deng, M.D.	Hydrogen 3, Phosphorus 32, Sulfur 35, Chromium 51
Patricia K. Eagon, Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Iodine 125
Howard D. J. Edington, M.D.	Hydrogen 3, Chromium 51
Roy A. Frye, M.D., Ph.D.	Carbon 14, Phosphorus 32, Phosphorus 33, Sulfur 35
Yingchieh Hsu, Ph.D.	Cesium 137 for instrument calibration
Yisrael Isaacson, M.D., Ph.D.	Hydrogen 3, Carbon 14
Richard Kim, M.D.	Sulfur 35

Authorized Users	Material and Use
Mark L. Jordan, M.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Chromium 51, Iodine 125
David E. Kelly, M.D.	Tritiated Oleate and Tritiated Glucose for human research,
Arnold Meisler, M.D.	Hydrogen 3, Phosphorus 32, Sulfur 35, Iodine 125
John W. Mellors, M.D.	Hydrogen 3, Phosphorus 32, Sulfur 35
David C. Whitcomb, M.D., Ph.D.	Hydrogen 3, Sulfur 35, Phosphorus 32, Iodine 125
Chandrashekhar Gandhi, Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Sulfur 35, Calcium 45, Iodine 125
Rebecca K. Studer, Ph.D.	Hydrogen 3, Phosphorus 32, Sulfur 35
Jeffrey Yao, Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Sulfur 35, Iodine 125
Steven H. Graham, M.D., Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Phosphorus 33, Sulfur 35, Iodine 125
G. David Roodman, M.D., Ph.D.	Hydrogen 3, Carbon 14, Phosphorus 32, Sulfur 35, Iodine 125
Chandrakant R. Patel, M.D.	35.100, 35.200, 35.300, *in vitro* studies, Gadolinium 153
Susan Geletka, M.D.	**35.100, 35.200, *in vitro* studies, Gadolinium 153**
Rupal Bandi, MBBS	**35.100, 35.200, *in vitro* studies, Gadolinium 153**

13. Permitted material shall not be used in or on humans except as provided otherwise by specific condition of this permit.

14. The permittee shall not use permitted material in field applications where the activity is released except as provided otherwise by specific condition of this permit.

15. Experimental animals, or the products from experimental animals, that have been administered permitted materials shall not be used for human consumption.

16. This permit does not authorize commercial distribution of permitted material.

17. For sealed sources not associated with 10 CFR 35 use, the following conditions apply:

    A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified by the certificate of registration issued by the Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

    B. Notwithstanding Paragraph A of this permit condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.

    C. Each sealed source fabricated by the permittee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

    D. In the absence of a certificate from a transferor indicating a leak test has been made within the intervals specified in the certificate of registration issued by the Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

    E. Sealed sources need not be tested if they contain only hydrogen 3, or they contain only a radioactive gas, or the half-life of the isotope is 30 days or less, or they contain not more than 100 microcuries of beta- and/or gamma-emitting material, or not more than 10 microcuries of alpha-emitting material.

F. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

G. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the National Health Physics Program in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Nuclear Regulatory Commission regulations.

H. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the permittee or by other persons specifically licensed by the Nuclear Regulatory Commission or an Agreement State to perform such services.

18. Sealed sources containing permitted material shall not be opened or sources removed from source holders by the permittee.

19. The permittee shall conduct a physical inventory every six months to account for all sealed sources and/or devices received and possessed under this permit. Records of inventories shall be maintained for five years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

20. A. Detector cells containing a [illegible]nium tritide foil or a scandium tritide foil [illegible]hall only be used in conjunction with a properly operating t[illegible]erature control mechanism which [illegible]ts the foil temperature from exceeding that specified b[illegible]nufacturer and approved b[illegible]lear Regulatory Commission.

B. When in use, detector cells [illegible]g a titanium tritide foil o[illegible]um tritide foil shall be vented to the outside.

21. Maintenance, repair, cleaning, replacement, and disposal of foils contained in detector cells shall be performed only by the device manufacturer or other persons specifically authorized by the Nuclear Regulatory Commission or an Agreement State to perform such services.

22. For radioactive material held for decay in storage other than that held in accordance with 10 CFR 35.92, the permittee is authorized to hold radioactive material with a physical half-life of less than 120 days for decay in storage before disposal in ordinary trash, provided:

A. Waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. A record of each such disposal permitted under this permit condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

23. The permittee is authorized to transport permitted material only in accordance with the provisions of 10 CFR 71, "Packaging and Transportation of Radioactive Material."

24. In addition to the possession limits in Item 8, the permittee shall further restrict the possession of permitted material as follows:

    A. For unsealed sources to quantities less than 10^5 times the applicable limits in Appendix B, 10 CFR 30 as specified in 10 CFR 30.35(d) and

    B. For sealed sources, to quantities less than 10^{10} times the applicable limits in Appendix B, 10 CFR 30 as specified in 10 CFR 30.35(d).

25. Incineration of permitted material for the purpose of disposal may be performed only as authorized by 10 CFR 20.2004(a)(2).

26. Except as specifically provided otherwise in this permit, the permittee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This permit condition applies only to those procedures required to be submitted in accordance with the regulations. Additionally, this permit condition does not limit the permittee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission regulations shall govern unless the statements, representations, and procedures in the permittee's application and correspondence are more restrictive than the regulations.

    A. Application dated April 11, 1991
    B. Application dated November 20, 1992
    C. Letter dated January 27, 1993
    D. Letter dated April 29, 1993
    E. Letter dated May 7, 1993
    F. Letter dated June 4, 1993
    G. Letter dated October 27, 1
    H. Letter dated August 17, 19
    I. Letter received September
    J. Letter dated September 21
    K. Letter dated September 22,
    L. Letter dated November 1, 19
    M. Letter dated January 23, 1997
    N. Letter dated December 4, 1997
    O. Letter dated February 1, 2000
    P. Letter dated April 23, 2002
    Q. Letter dated August 11, 2003 [Add authorized user, Dr. Patel; delete Dr. Durick]
    R. Facsimile dated February 27, 2004 [Add authorized users, Drs Geletka and Bandi]

FOR THE DEPARTMENT OF VETERANS AFFAIRS

Date MAR 17 2004

By E. Lynn McGuire
Director, National Health Physics Program
North Little Rock, AR

Amendment No. 6

OHIO DEPARTMENT OF HEALTH

LICENSE FOR RADIOACTIVE MATERIAL

Pursuant to Chapter 3748 of the Ohio Revised Code, and in reliance on statements and representations made by the licensee, a license is hereby issued authorizing the licensee named herein to receive, acquire, possess, and transfer radioactive material as designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the applications of Chapter 3748 of the Ohio Revised Code and all rules promulgated thereunder. This [illegible] Administrative Code and is subject to all applicable rules, regulations and orders of the Ohio Department of Health now or hereinafter in effect and to any conditions specified below.

LICENSEE	LICENSE NUMBER
1. Bucyrus Community Hospital	3. 02120170000
2 629 N. Sandusky Ave. Bucyrus, Ohio 44820	EXPIRATION DATE 4. August 1, 2003
	BUREAU DOCKET NUMBER 5. DC27-12-97

6. RADIOACTIVE MATERIAL	7. CHEMICAL AND/OR PHYSICAL FORM	8 MAXIMUM QUANTITY THAT LICENSEE MAY POSSESS AT ANY ONE TIME UNDER THIS LICENSE
A Any radioactive material identified in 10 CFR 35.100	A Any radiopharmaceutical form	A. As needed
B. Any radioactive material identified in 10 CFR 35.200	B Any radiopharmaceutical form	B. As needed
C. Any radioactive material identified in 10 CFR 35.300	C. Any radiopharmaceutical form	C. As needed not to exceed 370 GBq (10 Ci) of Iodine-131
D Cobalt - 57	D Sealed source	D. As needed, no single source to exceed 555 MBq (15 mCi)

9 Authorized Use

A. Uptake, Dilution and Excretion studies per 10 CFR 35.100, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.

B Diagnostic Imaging and Localization per 10 CFR 35.200 (excluding xenon-133), as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.

C Therapeutic use of radioactive material per 10 CFR 35.300, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.

D Check, calibration and reference sources.

CONDITIONS

10 Licensed material may only be used at the licensee's facilities located at.

629 N. Sandusky Ave.
Bucyrus, Ohio 44820

11 The Radiation Safety Officer or Person in Charge of the radioactive material for this license is

Robert E. Peterson Jr.

OHIO DEPARTMENT OF HEALTH	Page 2 of 2
LICENSE FOR RADIOACTIVE MATERIALS	License Number 02120170000
SUPPLEMENTARY SHEET	Bureau Docket Number DC27-12-97
	Amendment No. 6

12. Licensed material shall be used by, or under the supervision of, individual(s) designated in writing.

Authorized User(s):	Material and Use
A. Susan Geletka, M.D.	A. 10 CFR 35.100, 35.200 and 35.300 (excluding Iodine-131 for treatment of thyroid carcinoma)
C. Mary Jean Wall, M.D	C. 10 CFR 35.100, 35.200 and 35.300.

13. All sealed sources that are used or obtained shall have been evaluated and approved by the U.S. Nuclear Regulatory Commission under the provisions of 10 CFR 32.210, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code, an equivalent agreement state regulation or NARM licensing state.

14. All persons performing activities meeting the definition of "Nuclear Medicine Technologist" as specified in R.C. 4773.01 shall be licensed and in good standing with the State of Ohio.

15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of sealed source licensed material to quantities below the minimum limit specified in rule 3701:1-40-17(C) of the Ohio Administrative Code for establishing decommissioning financial assurance.

16 Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Ohio Department of Health's statutes, rules, and orders shall govern unless statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations

A. Application dated May 15, 1998 ;

B Letters dated July 1, 1998 and July 8, 1998;

C Letters dated September 28, 1999,

D. Letter of correspondence dated January 7, 2000, and as listed on NRC license 34-15469-01, Amendment 19, dated November 11, 1993.

E Letter dated August 23, 2000

F Letter dated December 19, 2001 and facsimile dated December 28, 2001.

G Letter dated May 1, 2002 (a l items requested in amendment completed except item 4 close out of an area of use. This requires decommissioning approval.)

H. *Decommissioning approved release of area (treadmill) for unrestricted use in letter dated August 14, 2002.*

For the Ohio Department of Health

DATE: 8/25/02

BY: Roger L. Suppes for
Director, Ohio Department of Health

C FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 2 PAGES
Amendment No. 17

MATERIALS LICENSE

rsuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations retofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, urce, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to liver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license all be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all plicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified low.

Licensee	In accordance with the letter dated April 1, 1998
East Liverpool City Hospital	3. License number 34-15661-01 is amended in its entirety to read as follows:
425 West Fifth Street	4. Expiration date July 31, 2004
East Liverpool, OH 43920	5. Docket No. 030-09551 Reference No.

Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding xenon-133 and generators)	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed (not to exceed 1 curie of Iodine-131)

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200 (excluding xenon-133 and generators).

C. Medical use described in 10 CFR 35.300.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at East Liverpool City Hospital, 425 West Fifth Street, East Liverpool, Ohio.

11. Radiation Safety Officer: Harry K. Lah, M.D.

COPY 5

U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 2 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number: 34-15661-01 Docket or Reference Number: 030-09551 Amendment No. 17

12. Licensed material listed in Item 9 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A. Harry K. Lah, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300.
B. Paul Won Lim, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300.
C. Susan Gelatka, M.D.	10 CFR 35.100, 35.200 (excluding xenon-133 and generators) and 35.300 (excluding iodine-131 for treatment of thyroid carcinoma).
D. Randall Henry, M.D.	10 CFR 35.100 and 35.200 (excluding xenon-133 and generators)

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial [redacted]

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations and procedures contained in the documents, including any enclosures, listed below, except for those [illegible] medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated June 8, 1994; and

B. Letter dated April 1, 1998.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date APR 15 1998

By Michael F. Weber
Michael F. Weber
Nuclear Materials Licensing Branch
Region III

COPY

This is to acknowledge the receipt of your letter/application dated

5/5/2005, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment 37-30623-01

☒ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 137057.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader

	:	(FOR LFMS USE)
	:	INFORMATION FROM LTS
BETWEEN:	:	----------
	:	
License Fee Management Branch, ARM	:	Program Code: 02201
and	:	Status Code: 0
Regional Licensing Sections	:	Fee Category: 7C
	:	Exp. Date: 20110331
	:	Fee Comments: _____
	:	Decom Fin Assur Reqd: N
	::	

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED
   Applicant/Licensee: LIONS MEDICAL CENTER
   Received Date: 20050518
   Docket No: 3035648
   Control No.: 137057
   License No.: 37-30623-01
   Action Type: Amendment

2. FEE ATTACHED
   Amount: /
   Check No.: _____

3. COMMENTS

Signed Rebecca Jurnack
Date 5/19/2005

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
   Amendment _____
   Renewal _____
   License _____

3. OTHER _____
   _____

Signed _____
Date _____